

Emma Höglund appointed as new CEO of Neobiomics

Stockholm Febr 20, 2024 – Emma Höglund, is appointed as new Chief Executive Officer (CEO) of Neobiomics, starting her position on April 15, 2024. Stefan Johansson, co-founder and current CEO, will take on a new position as Chief Medical Officer (CMO).

Emma Höglund brings more than 15 years of experience from the healthcare industry including international commercial roles in the life sciences (MSD/Merck & Co and Novartis) and most recently from the Real-World-Data industry (BCB Medical). Her track record involves driving growth, strategic business development and global product launches while developing strong teams to achieve results. Emma holds an M.Sc. in Economics & Business from the Stockholm School of Economics.

With this recruitment, Stefan Johansson will be focusing on the R&D aspects of current and future products. Like before, he will keep working part-time as consultant neonatologist in Stockholm.

Stefan Johansson comments: *“I am so glad Emma Höglund is joining Neobiomics. Her extensive experience in leading change will enable us to take new and important steps in developing Neobiomics and making an even bigger impact.”*

“I am truly excited to take on this new role and together with the team lead Neobiomics into its next phase. My professional purpose lies in making healthcare products and services contribute to better health. Neobiomics is uniquely positioned to provide innovative products, improving care for newborns and their families”, says Emma Höglund.

About Neobiomics

Neobiomics is an innovative and fast-growing company located at the Karolinska Institutet Science Park in Stockholm, Sweden. Founded in 2016, Neobiomics develops specialised food supplements in the neonatal nutrition niche. As of today, Neobiomics provides two products. ProPrems®, developed in collaboration with Novonesis in Denmark (former Chr.Hansen A/S), is a high-quality and well-documented bifidobacterial blend implemented by more than 150 health care providers within and outside Europe. NeoMega36® is a tailor-made oil enriched with arachidonic acid and DHA, recently launched as a Food for Special Medical Purposes (FSMP). Since 2023, Neobiomics has a wholesale dealer authorisation, enabling future distribution of pharmaceutical products for pediatric and neonatal hospital care.





For further information, please contact:

Emma Höglund, +46 703 030 138
Staffan Thunell, chairman of the Board of Directors +46 70 876 90 90
Stefan Johansson, +46 703 49 59 47

info@neobiomics.eu



Neobiomics AB
Fogdevreten 2A
171 65 Solna
SWEDEN

info@neobiomics.eu

VAT-nb SE559072218601